There has been growing interest in the potential value of pre-transplant inflammatory markers as predictors of outcomes in transplant patients. The most widely studied marker of inflammation is C-Reactive Protein (CRP), an acute phase reactant protein synthesized by the liver in response to interleukin 6, tumor necrosis factor- α and interleukin 1β. High levels of CRP, therefore, are reflective of a pro-inflammatory state. Moreover, CRP also has pro-inflammatory effects of its own such as complement activation and stimulation of natural killer cell activity. There is a substantial existing body of literature on the predictive value of serum CRP measurements, even at a single point in time, in adults with chronic kidney disease. CRP levels are elevated in adults with chronic kidney disease, even in the early stages, with levels being even higher in dialysis patients. High serum levels of CRP are predictive of future cardiac disease and mortality in dialysis patients, patients with coronary artery disease and even in healthy individuals. There are much less data on the predictive value and role of CRP in the post-transplant population, which potentially has more to gain from the identification of a non-invasive biomarker that could predict adverse events. The purpose of this review is to discuss the data pertaining to the utility of CRP measurements in adults and children after transplantation.
|Original language||English (US)|
|Title of host publication||C-Reactive Protein: New Research|
|Publisher||Nova Science Publishers, Inc.|
|Number of pages||8|
|State||Published - 2009|
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)